REPL - Replimune Group Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

290.8M

Cash

420.7M

Avg Qtr Burn

-46.37M

Short % of Float

15.36%

Insider Ownership

4.83%

Institutional Own.

90.70%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RP1 +Opdivo Details Cancer, Melanoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 + Opdivo Details Cancer, Non-melanoma skin cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 + Libtayo (cemiplimab) Details Cutaneous squamous cell carcinoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP1 Details Cutaneous squamous cell carcinoma, Cancer, Skin cancer, Kidney transplantation, Liver transplant	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP2 + Opdivo Details Cancer, Uveal melanoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP2 +/- Opdivo Details Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details Cancer, Colorectal cancer , Hepatocellular carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP3 in comb w/std. of care Details Cancer, Head and neck squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
RP3 +/- Opdivo Details Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.